Enanta Pharmaceuticals (ENTA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ENTA Enanta Pharmaceuticals

Watchlist

6.280
+0.420+7.17%

Close Dec 20 16:00 ET

6.280
0.0000.00%

Post 17:22 ET

133.10MMarket Cap-1.15P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Enanta Pharmaceuticals: Undervalued Potential Beyond Hepatitis C – Buy Recommendation by Roy Buchanan
TipRanksDec 13 10:05 ET
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $20
Moomoo NewsDec 11 08:31 ET · Ratings
Insider Sale: Chief Product Strategy Officer of $ENTA (ENTA) Sells 2,283 Shares
Quiver QuantitativeDec 10 17:18 ET
Oppenheimer Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating, Maintains Target Price $14
Moomoo NewsDec 10 08:31 ET · Ratings
Enanta Pharmaceuticals (ENTA) Gets a Hold From Oppenheimer
TipRanksDec 10 08:07 ET · Ratings
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $21
Moomoo NewsDec 9 14:31 ET · Ratings

Comments

thoughtful Narwhal_3

Dec 9 05:49

$Enanta Pharmaceuticals (ENTA.US)$ topline data looks good

Jaguar8

Dec 9 05:32

NEWS

$Enanta Pharmaceuticals (ENTA.US)$
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
• Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2
• Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified ...

This_Guy

Dec 9 05:32

$Enanta Pharmaceuticals (ENTA.US)$
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Positive
Achieved primary endpoint with 1.4 log viral load decline at Day 5 in Part 2
Demonstrated favorable safety profile with no treatment discontinuations
Received FDA Fast Track designation
Successfully achieved target drug exposure levels across all age groups
Showed 1.2 log viral loa...

Moomoo AI

Mar 5 20:53

Enanta Pharmaceuticals' P/S ratio remains low despite recent share price jump, likely due to weak revenue forecast. Market sentiment doesn't anticipate a strong share price rise soon.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Moomoo AI

Feb 12 05:23

Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.